Anticoagulation with Enoxaparin in Patients with Obesity
Anticoagulation in Patients with Obesity
Abstract
Obesity is a relatively common characteristic in modern western world populations and has a significant impact on the person’s health status. Despite the fact that it constitutes a well-described risk factor for thromboembolic events, the optimal anticoagulation strategy in obese patients remains vague. The available data suggest that while standard fixed enoxaparin doses (for prophylactic purposes) can lead to subtherapeutic effect, the conventional weight-based dosing schemes may result in overtreatment. Although not particularly strong, contemporary evidence indicate that a dose reduction in morbidly obese patients will likely result in a therapeutic anti-Xa level without an increased probability for bleeding or VTE. Rhythmos 2021;16(2):34-38.
Downloads
Published
Versions
- 2021-04-15 (2)
- 2021-04-15 (1)
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
